Salivary Duct Carcinoma of the Parotid Gland: Is Adjuvant HER-2-Targeted Therapy Required?

The present results have also suggested that HER-2 overexpression is associated with a poor prognosis. Therefore, HER-2 status should be evaluated at least in the presence of advanced SDC, and targeted therapy should be considered in the adjuvant setting.